Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
RARE Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
30%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
187.30%
RARE Stock Analysis
RARE
PE Ratio:
RARE
PEG Ratio:
Not Available
RARE
Forward EPS Growth (12 month):
0.00%
RARE
PS Ratio:
3.3
RARE
PSG Ratio:
0.1
RARE
Forward Revenue Growth (12 month):
32.60%
RARE Articles
No data was found